No quarterly revenue total was found in Grace Therapeutics, Inc.'s SEC filings.
Grace Therapeutics, Inc. (GRCE) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-15.79M
-369.7% vs year-ago quarter
Operating cash flow
$-3.22M
-78.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.91
-333.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
21.04M
+52.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRCE (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1444192
- Former names
- Acasti Pharma Inc. (until Oct 25, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
Q1 FY2026 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$15.9M | -$3.0M | -$2.4M | -$2.5M | -$3.1M |
| Net income | -$15.8M | -$1.2M | -$2.3M | -$938,000 | -$3.4M |
| Diluted EPS | -$0.91 | -$0.07 | -$0.14 | -$0.06 | -$0.21 |
| Operating cash flow | -$3.2M | -$1.7M | -$2.2M | -$3.1M | -$1.8M |
| Total assets | $50.1M | $66.7M | $68.5M | $66.6M | $69.8M |
| Total liabilities | $1.9M | $2.8M | $3.6M | $3.8M | $6.3M |
| Stockholders' equity | $48.2M | $63.9M | $64.9M | $62.8M | $63.5M |
| Cash and investments | $13.8M | $17.0M | $18.7M | $16.9M | $20.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 18, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 6, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 18, 2026 |
All 593 Grace Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.